1. American Heart Journal
Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II) 
Benjamin A. Steinberg, MD, MHS, Peter Shrader, MA, Laine Thomas, PhD, Jack Ansell, MD, Gregg C. Fonarow, MD, Bernard J. Gersh, MB, ChB, DPhil, Elaine Hylek, MD, MPH, Peter R. Kowey, MD, Kenneth W. Mahaffey, MD, Emily C. O'Brien, PhD, Daniel E. Singer, MD, Eric D. Peterson, MD, MPH, Jonathan P. Piccini, MD, MHS 
American Heart Journal 
Volume 189, Pages (July 2017)
DOI: /j.ahj
Copyright © 2017 The Author(s) Terms and Conditions

2. Figure 1
Use of NOAC versus warfarin in selected subgroups of patients with new-onset AF. *P<.05, **P< GIB, gastrointestinal bleeding; PCP, primary care physician; EP, electrophysiology.
American Heart Journal  , 40-47DOI: ( /j.ahj )
Copyright © 2017 The Author(s) Terms and Conditions

3. Figure 2
Histogram of individual oral anticoagulant use in patients with new-onset AF treated with any anticoagulation across sites for (A) warfarin, (B) dabigatran, (C) rivaroxaban, and (D) apixaban.
American Heart Journal  , 40-47DOI: ( /j.ahj )
Copyright © 2017 The Author(s) Terms and Conditions